SB
The startup develops therapeutic products that enable ultra-rapid delivery of biologics and nucleic acids directly into gastrointestinal tissues, targeting inflammatory-mediated diseases. This platform enhances the efficacy of treatments by facilitating the direct administration of small molecules, proteins, vaccines, and nucleic acids, improving patient recovery from gastrointestinal conditions.
Updated 3 months ago
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops therapeutic products that enable ultra-rapid delivery of biologics and nucleic acids directly into gastrointestinal tissues, targeting inflammatory-mediated diseases. This platform enhances the efficacy of treatments by facilitating the direct administration of small molecules, proteins, vaccines, and nucleic acids, improving patient recovery from gastrointestinal conditions.